development

γ-Aminobutyric acid (4-Aminobutyric acid) is the predominant inhibitory neurotransmitter in the central nervous system.

MAK683 hydrochloride embryonic ectodermal development (EED) inhibitor, also a potent PRC2 inhibitor, blocked cancer cell proliferation (IC50=1.014nM), with IC50 values of 59, 26, and 89 nM measured in EED Alphascreen, ELISA, and LC-MS assays, respectively.

5-O-Cinnamoylquinic acid is a natural product.

p,p'-DDE (p,p'-dichlorodiphenyldichloroethylene) is a metabolite and degradation product of the organochlorine pesticide DDT

PF-04885614 is a potent inhibitor of NaV1.8, has potential for neurological and neurodevelopmental diseases treatment.

Ecdysone is a major steroid hormone in insects and herbs. Ecdysone triggers mineralocorticoid receptor activation and induces cellular apoptosis. Ecdysone signaling through Ecdysone receptor isoform B1 is required cell autonomously for the muscle death.

Gefitinib (ZD1839) is an EGFR first-generation inhibitor with oral activity that inhibits the EGFR 19 Del and L858R mutations. Gefitinib has antitumor activity and is used for the treatment of EGFR-mutated non-small-cell lung cancers. Gefitinib administration RESULTS in the development of the EGFR C797S resistance mutation.

IAXO-102 is a TLR4 antagonist that negatively regulates TLR4 signaling by inhibiting MAPK and p65 NF-κB phosphorylation, as well as the expression of TLR4-dependent proinflammatory proteins. It also prevents the development of experimental abdominal aortic aneurysm.

1. Ginkgetin has anti-influenza virus and anti-fungal activities. 2. Ginkgetin has anti-inflammatory activity, can down-regulates COX-2 induction in vivo against skin inflammatory responses. 3. Ginkgetin is a good STAT3 inhibitor and may be a useful lead

Docosahexaenoic Acid (DHA) is an essential omega-3 fatty acid prevalent in the brain and retina.

SM-102 is the only ionizable amino cationic lipid currently clinically approved for RNA therapeutics and can be used to synthesize lipid nanoparticles (LNPs). It shows potential in the development of LNPs for the delivery of mRNA-based vaccines.

CPPHA, a positive allosteric modulator of glutamate receptors mGluR5 and mGluR1, is commonly used in development for central nervous system diseases.

FUREGRELATE, a thromboxane A2 (TxA2) synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets.

para-Nitroblebbistatin is a non-cytotoxic, non-fluorescent, photostable, and specific inhibitor of myosin II. para-Nitroblebbistatin can be used to study the specific roles of myosin II in physiology, development, and cell biology.

Topterone (Win 17,665) is a potent topical antiandrogen that inhibits the stimulation of lumbar organ development by testosterone and dihydrotestosterone in castrated immature male hamsters.

Epsilon-momfluorothrin (Momfluorothrin, (Z,1R,3R)-), a type I synthetic pyrethroid insecticide, exerts its insecticidal properties and triggers activation of the constitutive androstane receptor (CAR). Notably, its administration in rats has been observed to induce the development of hepatocellular tumors.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders[1].

MAK683 is an inhibitor of embryonic ectoderm development (EED) (IC50s: 59, 89, 26 nM in EED Alphascreen binding, LC-MS and ELISA assay).

CBHcy is a dual-substrate analogue, a specific BHMT inhibitor that causes betaine-homocysteine S-methyltransferase (BHMT) to adopt the same conformation as the ternary complex, potentially inducing the development of cysteinemia.

Naxillin is a non-growth hormone-like molecule that induces lateral root development by positively affecting the IBA to IAA transition at specific sites in the root.

(Rac)-Daglutril (SLV 306 acetic acid) is the racemate form of Daglutril. Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.

DSM421 (DSM-421) is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown activity against field isolates of both P. falciparum and P. vivax.

Finrozole (MPV 2213ad) is a novel selective aromatase inhibitor that is partially reversible for breast development.

Anisperimus (LF 15-0195) is an immunosuppressant that enhances activation-induced T-cell death by promoting caspase-8 and caspase-10 activation at the DISC level, and prevents CNS autoimmunity by promoting the development of Foxp3-expressing regulatory CD4 T cells.